NEW YORK (GenomeWeb News) – The Broad Institute of MIT and Harvard has bought 22 new Genome Analyzers, nearly doubling its stock of the Illumina-made sequencers, the company said today.

Broad conducts a wide range of biomedical genomics projects, and has worked in a partnership with the San Diego-based life sciences company. Before this purchase, Broad already had 25 of the analyzers in its tool shed, the company said.

In the coming year, Illumina said that it plans to increase the throughput of the analyzer to as much as 95 gigabases of DNA sequence data per run.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.